Clinical Trials

Sanofi and GSK announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase 3 evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate. “Over the...

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, and NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research...

Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines administered by tablet, announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its oral COVID-19 tablet vaccine candidate was generally well-tolerated, and immunogenic as measured by multiple...

The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new...

Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced early positive data from its ongoing U.S. Phase I controlled, observer-blinded clinical trial of inhaled Ampion versus standard of care for...

Aizon launches its Bioreactor Application, the pharma industry’s first predictive analysis and deep knowledge management application. The Aizon Bioreactor Application adds the bioreactor process to the “Smart Manufacturing” transformation that is accelerating across the Pharma and Biotech industry. Aizon...

Rigel Pharmaceuticals, Inc. announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel's ongoing Phase 3 clinical trial to evaluate...